ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,933.44
0.28%
US Tech 100
20,086.80
-0.20%
Dow Jones
43,767.43
0.83%
Brent Oil
73.505
0.91%
Bitcoin
97,044.62
2.85%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Larimar Therapeutics Inc (LRMR) Quote

Larimar Therapeutics Inc

Larimar Therapeutics Inc (LRMR)

NASDAQ
6.12
0.04
( 0.66% )
Updated: 11:20:28
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
6.12
Bid
6.10
Ask
6.12
Volume
311,171
5.68 Day's Range 6.16
3.0499 52 Week Range 13.68
Market Cap
390.497M
Previous Close
6.08
Open
6.12
Last Trade
1
@
6.11
Last Trade Time
11:20:27
Financial Volume
$ 1,862,355
VWAP
5.985
Average Volume (3m)
745,632
Shares Outstanding
63,806,628
Dividend Yield
-
PE Ratio
-1.71
Earnings Per Share (EPS)
-0.58
Revenue
-
Net Profit
-36.95M

About Larimar Therapeutics Inc

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion p... Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
larimartx.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Larimar Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker LRMR. The last closing price for Larimar Therapeutics was $6.08. Over the last year, Larimar Therapeutics shares have traded in a share price range of $ 3.0499 to $ 13.68.

Larimar Therapeutics currently has 63,806,628 shares outstanding. The market capitalization of Larimar Therapeutics is $387.94 million. Larimar Therapeutics has a price to earnings ratio (PE ratio) of -1.71.

Ask ADVFN Intelligence (AI)

LRMR Latest News

More News

Form 8-K - Current report

November 18 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

November 14 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

October 30 2024
Edgar (US Regulatory)

Form 8-K - Current report

October 30 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

August 08 2024
Edgar (US Regulatory)

Form 8-K - Current report

August 07 2024
Edgar (US Regulatory)

Form 8-K - Current report

June 10 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 31 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

May 31 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.81-22.82471626737.938.145.687993036.48744937CS
4-1.24-16.8478260877.369.55.687544187.86884882CS
12-1.94-24.06947890828.069.55.687456327.35318187CS
26-1.93-23.97515527958.0511.25.686135367.85731701CS
522.9995.52715654953.1313.683.04995166678.21348017CS
156-4.13-40.292682926810.2513.681.532949176.44066893CS
260-5.88-491225.871.532229827.21836967CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
$ 1.892
(93.06%)
105.42M
CRNCCerence Inc
$ 5.17
(83.33%)
32.73M
BDRXBiodexa Pharmaceuticals PLC
$ 6.13
(59.22%)
3.73M
IBGInnovation Beverage Group Limited
$ 1.1309
(42.93%)
6.83M
SPAISafe Pro Group Inc
$ 4.4871
(40.22%)
38.45M
PYXSPyxis Oncology Inc
$ 2.055
(-46.20%)
9.59M
GLXGGalaxy Payroll Group Ltd
$ 2.20
(-43.73%)
507.51k
KURAKura Oncology Inc
$ 9.99
(-37.21%)
7.54M
BLRXBioLineRx Ltd
$ 0.3571
(-34.50%)
5.72M
SHOTWSafety Shot Inc
$ 0.1001
(-33.27%)
2.5k
CDTConduit Pharmaceuticals Inc
$ 0.1109
(20.15%)
490.48M
NVDANVIDIA Corporation
$ 143.81
(-1.43%)
205.05M
AKTSAkoustis Technologies Inc
$ 0.1014
(16.42%)
183.54M
ELABElevai Labs Inc
$ 0.0201
(-6.07%)
150.44M
WORXSCWorx Corporation
$ 1.892
(93.06%)
105.42M

LRMR Discussion

View Posts
tw0122 tw0122 4 months ago
LRMR above $9 momentarily
👍️0
Monksdream Monksdream 7 months ago
LRMR under $10

👍️0
Monksdream Monksdream 8 months ago
LRMR under $10
👍️0
Monksdream Monksdream 9 months ago
LRMR new 52 week high
👍️0
Monksdream Monksdream 9 months ago
LRMR new 52=week high
👍️0
AJ Freely AJ Freely 1 year ago
$LRMR - Announced that the FDA has cleared the Company’s four-week, placebo-controlled, Phase 2 dose exploration trial of CTI-1601
👆Up 8% Pre-Market/ Current Price $3,40
👍️0
magacrew2020 magacrew2020 2 years ago
could probably get through approval on just 25 mg if they are going to approve reta
👍️0
subslover subslover 2 years ago
The company said it received feedback from the FDA on information needed to resolve CTI-1601's current clinical hold, as well as a proposed change for a second phase. CTI-1601 is a treatment for Friedreich's ataxia.

Larimer plans to submit a complete response to CTI-1601's clinical hold in the third quarter.

Larimar is also proposing a phase two, four-week dose exploration study in Friedreich's ataxia patients. Friedreich's ataxia is a rare disease that causes progressive nervous system damage and movement problems, usually beginning during childhood.
👍️0
JJJ54 JJJ54 3 years ago
I voted NO on the 2022 Annual Meeting Vote. I recommend you do the same.
👍️0
DarkPool DarkPool 3 years ago
Interesting.
👍️0
oxnous oxnous 4 years ago
Waking up . But volume should be higher.
👍️0
DewDiligence DewDiligence 4 years ago
LRMR 2Q20 results—6/30/20 cash=$113.7M:

https://www.globenewswire.com/news-release/2020/08/11/2076240/0/en/Larimar-Therapeutics-Reports-Second-Quarter-2020-Operating-and-Financial-Results.html

No CC.
👍️0
casenumber casenumber 4 years ago
Large chunks are being gobbled
Whales are lurking around?
👍️0
subslover subslover 4 years ago
The company they are merging with looks pretty darn impressive
https://chondrialtherapeutics.com/
👍️0
casenumber casenumber 5 years ago
Volume!
👍️0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-26-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-24-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
whytestocks whytestocks 5 years ago
News: $ZFGN Penny Stocks To Buy Or Sell Before The End Of 2019?

These Penny Stocks Moved Big But Can They Continue Higher Before Next Year? Over the course of the year, plenty of penny stocks have generated significant gains for investors. Even as the year comes to a close, there are some penny stocks that are gaining momentum. It is often said that inve...

Got this from ZFGN - Penny Stocks To Buy Or Sell Before The End Of 2019?
👍️0
Fat Thor Fat Thor 5 years ago
Like I said at .67 cents
👍️0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-23-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 years ago
Wow...guess they will satisfy the 1dollar minimum nasd requirement with out rs.....
This will be huge when ticker change and merger consummated next month!

Scrap the notice of delisting boys.....

82M cash and 30M OS....sounds fun!
👍️0
ClayTrader ClayTrader 5 years ago
* * $ZFGN Video Chart 12-20-2019 * *

Link to Video - click here to watch the technical chart video

👍️0
casenumber casenumber 5 years ago
Over a buck soon when ticker change completed....
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
exactly is great
👍️0
Fat Thor Fat Thor 5 years ago
Probably 3-9 months away still - appears to be a massive over correction and tax loss selling on the merger news. Just a short target at the moment. They will run this in Q1 pre-split to get a much more favorable ratio IMO. Let's see what happens. Lots of cash on hand here at very low burn rate per Q.

The transaction is expected to close in the first half of 2020, subject to approvals by stockholders of each company and other customary closing conditions.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
R/Split coming per 8k today
👍️0
Fat Thor Fat Thor 5 years ago
December discounts. With 85 million in cash, a merger, and priced at 67 cents there's no way this doesn't run soon. 35 million O/S.
👍️0
casenumber casenumber 5 years ago
Ticker change coming...Shorts will get burn if they will not cover or do damage control.
ZFGN has 82M dollars in cash!

The proposed merger will result in a combined publicly traded, clinical-stage biopharmaceutical company operating under a new name, Larimar Therapeutics, Inc.
👍️0
casenumber casenumber 5 years ago
Shorts covering.. they have to before it gets out of control once the merger is official...
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
10 day MA live chart huge oversold,safe here now,will recover nice
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
bought 3k at 6391
👍️0
Fat Thor Fat Thor 5 years ago
Just saw a bunch come through on tape that were vastly different but didn't indicate "out of sequence"...they were either out of sequence or it was a messed up market order. Just odd. This one is clearly under short attack. Volume could squeeze it near term.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
ZFGN~~Balance Sheet
Total Cash (mrq) 82.01M
Total Cash Per Share (mrq) 2.19
Total Debt (mrq) 24.35M
Total Debt/Equity (mrq) 40.67
Current Ratio (mrq) 5.11
Book Value Per Share (mrq) 1.60
https://finance.yahoo.com/quote/ZFGN/key-statistics?p=ZFGN



👍️0
alchemytrader alchemytrader 5 years ago
not really. that would mean its been up and down, up and down. this is nothing but down..
👍️0
Fat Thor Fat Thor 5 years ago
...this price action is ALL over the place. Crazy.
👍️0
alchemytrader alchemytrader 5 years ago
man i hope so. just want out even now
👍️0
BoilerRoom BoilerRoom 5 years ago
$ZFGN in at .70
👍️0
BoilerRoom BoilerRoom 5 years ago
Short this
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
will recover but sucks,waste of time
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m.,
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
Conference Call Information
Zafgen and Chondrial Therapeutics will host an investor conference call today, December 18, 2019, at 8:30 a.m., Eastern Time, to discuss the merger as well as other forward-looking information. Investors and other interested parties may participate by dialing (844) 824-7428 in the United States or (973) 500-2177 outside the United States and referencing conference ID number 5688136. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations. A replay of this conference call will be available beginning at 11:30 a.m. ET on December 18, 2019 through December 25, 2019 by dialing (855) 859-2056 in the United States or (404) 537-3406 outside the United States. To access the replay please provide Conference ID number 5688136.
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
dont think so
👍️0
Widowsson32 Widowsson32 5 years ago
This is done no benefit to this company but ONTX will make you very rich
👍️0
alchemytrader alchemytrader 5 years ago
institutions selling off?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
the news is great,why?
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
fffffffffffffffffff MMS
👍️0
alchemytrader alchemytrader 5 years ago
i guess were screwed
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
f MMs
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
.79 f
👍️0
ALERTS100%to10000%GAIN ALERTS100%to10000%GAIN 5 years ago
what the heck is going on here?
👍️0

Your Recent History

NASDAQ
LRMR
Larimar Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved